Sanofi, Cel­lec­tis team up to pair Lem­tra­da with al­lo­gene­ic CAR-Ts; Bris­tol My­ers joins Evotec's dri­ve to ad­vance UK sci­ence

Sanofi is part­ner­ing up with Cel­lec­tis on their al­lo­gene­ic CAR-Ts.

Cel­lec­tis struck a deal to use the French phar­ma’s drug alem­tuzum­ab (Lem­tra­da, an MS agent) as part of its lym­phode­ple­tion reg­i­men — used to side­line host im­mune cells and im­prove CAR-T cell ex­pan­sion and per­sis­tence.

The Sanofi drug is al­ready used in some clin­i­cal tri­als, and now the phar­ma gi­ant is on the hook for clin­i­cal stud­ies as they en­gage in ne­go­ti­a­tions over a com­mer­cial pact. — John Car­roll

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.